Volumetric modulated arc therapy (VMAT) provides the conformality that enables three separate simultaneous pelvic malignancies to be treated radically–a case study

Callista V Raharjo, Colin Chen, F. Lam, S. O'Neill, J. Almeida, J. Turner, Robyn Levingston, Anna O’ Keefe, I. Quin, G. Fogarty
{"title":"Volumetric modulated arc therapy (VMAT) provides the conformality that enables three separate simultaneous pelvic malignancies to be treated radically–a case study","authors":"Callista V Raharjo, Colin Chen, F. Lam, S. O'Neill, J. Almeida, J. Turner, Robyn Levingston, Anna O’ Keefe, I. Quin, G. Fogarty","doi":"10.15406/ijrrt.2020.07.00271","DOIUrl":null,"url":null,"abstract":"Radiotherapy and surgery are both potential modalities for the definitive treatment of pelvic malignancies. Although surgery provides a histological specimen, enabling exact staging, radiotherapy is sometimes preferred as it provides patients the opportunity for organ conservation and therefore perhaps better quality post-treatment survivorship. Our case report details how three separate primary pelvic cancers (prostate, rectal, anal) in one patient were treated simultaneously with definitive radiotherapy. Patient was prescribed 80 Gy in 40 fractions to the planning target volume (PTV) prostate, 54 Gy to PTV anal canal, 45 Gy to the pelvis including PTV rectosigmoid junction and 36 Gy to the PTV inguinal lymph nodes that encompassed clinically negative nodes draining the anus, through the Volumetric Modulated Arc Therapy (VMAT) with 6MV photons. Mean doses to organs at risk (OAR) are 30.01 Gy to the bowel volume, 46.54 Gy to the bladder, 30.42 Gy to the femurs, and 61.84 Gy to the rectum. Radiation doses to the prostate and anal canal are consistent with conventional treatment doses with definitive radiotherapy. The rectal dose was accepted as part of the definitive treatment of rectal cancer following Endoscopic Mucosal Resection (EMR). This could only be achieved through the superior dose conformality of VMAT, maximising the dose given to tumour bearing PTV while minimising the dose to OARs which included normal pelvic structures. All three cancers remained under control at 4 years after treatment, with minimal late toxicity associated with the treatment received. Further RCTs in pelvic malignancies are needed to help clinicians and patients select the best treatments, to improve disease control while maintaining quality of survivorship.","PeriodicalId":214028,"journal":{"name":"International Journal of Radiology & Radiation Therapy","volume":"65 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiology & Radiation Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/ijrrt.2020.07.00271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Radiotherapy and surgery are both potential modalities for the definitive treatment of pelvic malignancies. Although surgery provides a histological specimen, enabling exact staging, radiotherapy is sometimes preferred as it provides patients the opportunity for organ conservation and therefore perhaps better quality post-treatment survivorship. Our case report details how three separate primary pelvic cancers (prostate, rectal, anal) in one patient were treated simultaneously with definitive radiotherapy. Patient was prescribed 80 Gy in 40 fractions to the planning target volume (PTV) prostate, 54 Gy to PTV anal canal, 45 Gy to the pelvis including PTV rectosigmoid junction and 36 Gy to the PTV inguinal lymph nodes that encompassed clinically negative nodes draining the anus, through the Volumetric Modulated Arc Therapy (VMAT) with 6MV photons. Mean doses to organs at risk (OAR) are 30.01 Gy to the bowel volume, 46.54 Gy to the bladder, 30.42 Gy to the femurs, and 61.84 Gy to the rectum. Radiation doses to the prostate and anal canal are consistent with conventional treatment doses with definitive radiotherapy. The rectal dose was accepted as part of the definitive treatment of rectal cancer following Endoscopic Mucosal Resection (EMR). This could only be achieved through the superior dose conformality of VMAT, maximising the dose given to tumour bearing PTV while minimising the dose to OARs which included normal pelvic structures. All three cancers remained under control at 4 years after treatment, with minimal late toxicity associated with the treatment received. Further RCTs in pelvic malignancies are needed to help clinicians and patients select the best treatments, to improve disease control while maintaining quality of survivorship.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
容积调节弧线疗法(VMAT)提供了合规性,使三个独立的盆腔恶性肿瘤同时得到彻底治疗
放疗和手术都是盆腔恶性肿瘤最终治疗的潜在方式。虽然手术提供了组织学标本,可以精确分期,但放疗有时更可取,因为它为患者提供了器官保存的机会,因此可能有更好的治疗后生存质量。我们的病例报告详细介绍了一位患者的三种不同的原发性盆腔癌(前列腺癌、直肠癌、肛门癌)如何同时接受明确的放射治疗。通过6MV光子的体积调制弧线治疗(VMAT),患者在计划靶体积(PTV)前列腺上给予80 Gy,在PTV肛管上给予54 Gy,在骨盆上给予45 Gy,包括PTV直肠乙状结肠结,在PTV腹股沟淋巴结上给予36 Gy, PTV腹股沟淋巴结包括临床阴性淋巴结引流肛门。对危险器官(OAR)的平均剂量对肠容量为30.01 Gy,对膀胱为46.54 Gy,对股骨为30.42 Gy,对直肠为61.84 Gy。前列腺和肛管的放射剂量与常规放射治疗剂量一致。直肠剂量被接受为内镜下粘膜切除(EMR)后直肠癌最终治疗的一部分。这只能通过VMAT的高剂量一致性来实现,即对带肿瘤的PTV给予最大剂量,而对包括正常骨盆结构的OARs给予最小剂量。所有三种癌症在治疗后4年仍得到控制,与所接受治疗相关的晚期毒性最小。需要进一步的盆腔恶性肿瘤随机对照试验来帮助临床医生和患者选择最佳治疗方法,在保持生存质量的同时改善疾病控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Very long-term of survival, 5 years and more in diffuse intrinsic pontine brainstem gliomas in children and adolescents treated with Radiotherapy and Nimotuzumab Radiological CT findings and time evolution in acute stroke: case report Adaptive radiotherapy from past to future frontiers Lesion-based radiotherapy of the ears, lips and eyelids for skin cancer Lesion-based radiotherapy for non-melanoma skin cancer of the lower legs with a focus on radiation induced ulcers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1